# Epigenetic regulation of transcription factor binding motifs promotes Th1 response in Chagas disease cardiomyopathy

Pauline Brochet, Barbara Maria Ianni, Laurie Laugier, Amanda Garage Frade, João Paulo Silva Nunes, Priscila Camillo Teixeira, Charles Mady, Ludmila Rodrigues Pinto Ferreira, Quentin Ferré, Ronaldo Honorato Barros Santos, et al.

► To cite this version:

Pauline Brochet, Barbara Maria Ianni, Laurie Laugier, Amanda Garage Frade, João Paulo Silva Nunes, et al. Epigenetic regulation of transcription factor binding motifs promotes Th1 response in Chagas disease cardiomyopathy. Frontiers in Immunology, 2022, 13, 10.3389/fimmu.2022.958200. hal-03831919

HAL Id: hal-03831919

https://amu.hal.science/hal-03831919

Submitted on 27 Oct 2022

HAL is a multi-disciplinary open access
archive for the deposit and dissemination of sci-
entific research documents, whether they are pub-
lished or not. The documents may come from
teaching and research institutions in France or
abroad, or from public or private research centers.

L'archive ouverte pluridisciplinaire HAL, est
destinée au dépôt et à la diffusion de documents
scientifiques de niveau recherche, publiés ou non,
émanant des établissements d'enseignement et de
recherche français ou étrangers, des laboratoires
publics ou privés.

<figure><img src="image_1.png" /></figure>

Distributed under a Creative Commons Attribution 4.0 International License
<figure><img src="image_2.png" /></figure>

Check for updates

OPEN ACCESS

EDITED BY
Steven O'Reilly,
STipe Therapeutics, Denmark

REVIEWED BY
Miguel Vicco,
GlaxoSmithKline, Belgium
Francisco Callejas Hernández,
New York University, United States
Jose Roberto Sotelo-Silveira,
Instituto de Investigaciones Biológicas
Clemente Estable (IIBCE),
Uruguay

*CORRESPONDENCE
Christophe Chevillard
christophe.chevillard@univ-amu.fr
Edecio Cunha-Neto
edecunha@gmail.com
Lionel Spinelli
lionel.spinelli@univ-amu.fr

†These authors have contributed
equally to this work

SPECIALTY SECTION
This article was submitted to
Inflammation,
a section of the journal
Frontiers in Immunology

RECEIVED 31 May 2022
ACCEPTED 26 July 2022
PUBLISHED 22 August 2022

CITATION
Brochet P, Ianni BM, Laugier L,
Frade AF, Silva Nunes JP, Teixeira PC,
Mady C, Ferreira LRP, Ferré Q,
Santos RHB, Kuramoto A,
Cabantous S, Steffen S, Stolf AN,
Pomerantzeff P, Fiorelli AI, Bocchi EA,
Pissetti CW, Saba B, Cândido DdS,
Dias FC, Sampaio MF, Gaiotto FA,
Marin-Neto JA, Fragata A,
Zaniratto RCF, Siqueira S, Peixoto GDL,
Rigaud VO-C, Bacal F, Buck P,
Almeida RR, Lin-Wang HT, Schmidt A,
Martinelli M, Hirata MH, Donadi EA,
Costa Pereira A, Rodrigues Junior V,
Puthier D, Kalil J, Spinelli L,
Cunha-Neto E and Chevillard C (2022)
Epigenetic regulation of transcription
factor binding motifs promotes Th1
response in Chagas
disease cardiomyopathy.
Front. Immunol. 13:958200.
doi: 10.3389/fimmu.2022.958200

Epigenetic regulation of
transcription factor binding
motifs promotes Th1
response in Chagas
disease cardiomyopathy

Pauline Brochet<fnref n="1" />, Barbara Maria Ianni², Laurie Laugier³,
Amanda Garage Frade²,⁴,⁵, João Paulo Silva Nunes<fnref n="1" />,²,⁴,⁵,
Priscila Camillo Teixeira²,⁴,⁵, Charles Mady⁶,
Ludmila Rodrigues Pinto Ferreira⁷, Quentin Ferré<fnref n="1" />,
Ronaldo Honorato Barros Santos⁸, Andreia Kuramoto²,
Sandrine Cabantous³, Samuel Steffen⁸,⁹, Antonio Noedir Stolf⁹,
Pablo Pomerantzeff¹⁰, Alfredo Inacio Fiorelli⁹,
Edimar Alcides Bocchi⁹, Cristina Wide Pissetti¹¹, Bruno Saba¹²,
Darlan da Silva Cândido²,⁴,⁵, Fabrício C. Dias¹³,
Marcelo Ferraz Sampaio¹², Fabio Antônio Gaiotto⁸,⁹,
José Antonio Marin-Neto¹³, Abílio Fragata¹²,
Ricardo Costa Fernandes Zaniratto², Sergio Siqueira¹⁴,
Giselle De Lima Peixoto¹⁴, Vagner Oliveira-Carvalho Rigaud²,¹⁵,
Fernando Bacal⁸, Paula Buck¹⁰, Rafael Ribeiro Almeida²,⁴,⁵,
Hui Tzu Lin-Wang¹², André Schmidt¹³, Martino Martinelli¹⁴,
Mario Hiroyuki Hirata¹⁶, Eduardo Antonio Donadi¹³,
Alexandre Costa Pereira¹⁰, Virmondes Rodrigues Junior¹¹,
Denis Puthier<fnref n="1" />, Jorge Kalil²,⁴,⁵, Lionel Spinelli<fnref n="1" />,¹⁷*,
Edecio Cunha-Neto²,⁴,⁵*† and Christophe Chevillard<fnref n="1" />*†

<footnote n="1">¹Institut National de la Santé Et de la Recherche Médicale (INSERM), Unité Mixte de Recherche (UMR)
_1090, Aix Marseille Université, TAGC Theories and Approaches of Genomic Complexity, Institut MarMaRa,
Marseille, France,
²Laboratory of Immunology, Heart Institute Instituto do Coração (InCor), University of
São Paulo, School of Medicine, São Paulo, Brazil,
³Aix Marseille Université, Génétique et Immunologie des
Maladies Parasitaires, Inserm, UMR_906, Marseille, France,
⁴Division of Clinical Immunology and Allergy,
University of São Paulo, School of Medicine, São Paulo, Brazil,
⁵Instituto Nacional de Ciência e Tecnologia,
INCT, III- Institute for Investigation in Immunology, São Paulo, Brazil,
⁶Myocardiopathies and Aortic
Diseases Unit, Heart Institute Instituto do Coração (InCor), School of Medicine, University of São Paulo, São
Paulo, Brazil,
⁷RNA Systems Biology Laboratory (RSBL), Departamento de Morfologia, Instituto de Ciências
Biológicas, Universidade Federal de Minas Gerais, Belo Horizonte, Minas Gerais, Brazil,
⁸Division of
Transplantation, Heart Institute Instituto do Coração (InCor), University of São Paulo, School of Medicine,
São Paulo, Brazil,
⁹Division of Surgery, Heart Institute Instituto do Coração (InCor), University of São Paulo,
School of Medicine, São Paulo, Brazil,
¹⁰Heart Institute (InCor), School of Medicine, University of São Paulo,
São Paulo, São Paulo, Brazil,
¹¹Laboratory of Immunology, Universidade Federal Do Triângulo Mineiro
(UFTM), Uberaba, Brazil,
¹²Laboratório de Investigação Molecular em Cardiologia, Instituto de Cardiologia
Dante Pazzanese (IDPC), São Paulo, Brazil,
¹³School of Medicine of Ribeirão Preto Faculdade de Medicina
de Ribeirão Preto (FMRP), University of São Paulo, Ribeirão Preto, Brazil,
¹⁴Pacemaker Clinic, Heart Institute
Instituto do Coração (InCor), School of Medicine, University of São Paulo, São Paulo, Brazil,
¹⁵Heart Failure
Unit, Heart Institute Instituto do Coração (InCor) School of Medicine, University of São Paulo, São Paulo,
¹⁶Department of Clinical and Toxicological Analyses, Faculty of Pharmaceutical Sciences, University
of São Paulo (USP), São Paulo, Brazil,
¹⁷Aix Marseille Université, CNRS, INSERM, Centre d'Immunologie de
Marseille-Luminy, Marseille, France</footnote>
Chagas disease, caused by the protozoan *Trypanosoma cruzi*, is an endemic parasitic disease of Latin America, affecting 7 million people. Although most patients are asymptomatic, 30% develop complications, including the often-fatal Chronic Chagasic Cardiomyopathy (CCC). Although previous studies have demonstrated some genetic deregulations associated with CCCs, the causes of their deregulations remain poorly described. Based on bulk RNA-seq and whole genome DNA methylation data, we investigated the genetic and epigenetic deregulations present in the moderate and severe stages of CCC. Analysis of heart tissue gene expression profile allowed us to identify 1407 differentially expressed transcripts (DEGs) specific from CCC patients. A tissue DNA methylation analysis done on the same tissue has permitted the identification of 92 regulatory Differentially Methylated Regions (DMR) localized in the promoter of DEGs. An in-depth study of the transcription factors binding sites (TFBS) in the DMRs corroborated the importance of TFBS's DNA methylation for gene expression in CCC myocardium. TBX21, RUNX3 and EBF1 are the transcription factors whose binding motif appears to be affected by DNA methylation in the largest number of genes. By combining both transcriptomic and methylomic analysis on heart tissue, and methylomic analysis on blood, 4 biological processes affected by severe CCC have been identified, including immune response, ion transport, cardiac muscle processes and nervous system. An additional study on blood methylation of moderate CCC samples put forward the importance of ion transport and nervous system in the development of the disease.

KEYWORDS

dilated cardiomyopathy, Chagas disease, epigenetic, methylation, Th1 response, transcription factors

Introduction

Chagas disease is a neglected disease caused by the protozoan *Trypanosoma cruzi*. This parasite is endemic in 21 Latin America countries, where it affects around 7 million people through an insect vector, Reduviidae. With migratory flows, this disease can now be found in non-endemic countries (1). The clinical course of the disease comprises an acute phase, mostly asymptomatic, and a chronic phase, where 60% of the patients remain asymptomatic. However, 40% develop symptomatic disease, being 10% megaesophagus/megacolon, and 30% Chagas disease cardiomyopathy (CCC) with varying degrees of severity including refractory heart failure (1). This cardiomyopathy is the main cause of deaths from Chagas disease itself and is one of the most lethal cardiomyopathies (2). Some drugs are effective on *T. cruzi* only during the acute phase, but several side effects have been reported (3). The fact that the biological processes leading to CCC are not yet well understood has impaired the development of efficient therapeutic strategies.

The CCC myocardium displays a diffuse myocarditis with signs of inflammatory infiltrate and heart fiber damage, including significant fibrosis. The inflammatory infiltrate of CCC heart lesions is mainly composed of T cells displaying a Th1-like cytokine profile (4). This exacerbated Th1 response is characterized by a high expression of interferon-gamma (IFN-γ), tumor necrosis alpha (TNF-α) and TBX21 (T-bet) (5). Moreover, our group has previously demonstrated that CCC myocardium presents a unique gene expression profile, distinct from the other dilated cardiomyopathies (5, 6).

Many studies have highlighted the importance of DNA methylation in the regulation of gene expression in dilated cardiomyopathy (7), in particular by the methylation/ demethylation of transcription factor binding site (TFBS) located in genes regulatory regions (8). Development of severe CCC is also dependent of epigenetic regulations such as DNA methylation (9), but also involving miRNAs (6, 10) and lncRNAs (11). To get a more complete picture of the epigenomic landscape of CCC myocardium, we performed gene expression analysis (RNA-seq) complemented with a
methylation analysis (MethylationEPIC), covering 96% of gene
loci, including lncRNA.

# Methods

Ethical considerations

The protocol was approved by the institutional review boards of the University of São Paulo School of Medicine and INSERM (French National Institute of Health and Medical Research). Written informed consent was obtained from all patients. All experimental methods comply with the Helsinki Declaration.

Patients and myocardial tissue collection

Human left ventricular free wall heart tissue samples were obtained from patients with end-stage heart failure CCC at the time of heart transplantation (n=8). CCC patients underwent a serological diagnosis of *T. cruzi* infection and standard electrocardiography and echocardiography (12). Biopsies from controls (n=6) were obtained from healthy hearts of organ donors having no suitable recipient, and biopsies for dilated cardiomyopathy (DCM) from end-stage patients (n=8) (Supplementary Table 1).

RNA extraction and sequencing

Total RNAs were extracted from heart tissue samples as previously described (9). Ribosomal RNAs were depleted, and samples were prepared for sequencing according to the Illumina TruSeq RNA Preparation Kit and subjected to pairwise sequencing (2x150bp) with an Illumina HiSeq sequencer. This strategy allows to have information on only the most abundant non-coding RNAs. The RNA-seq data are available under the reference : (GEO accession: GSE191081).

Quality control and alignment

Raw data quality was verified with FastQC (v0.11.5)
and reads were filtered removing the adaptors and low-
quality based using Trimmomatic (v0.39). Reads were
aligned in paired-end mode on GRCh37 (hg19) human
reference genome using STAR (v2.5.4b), and gene
quantification was done with featureCounts (v2.0.0). All
bioinformatic analyses are available at https://github.com/
pbrochet/epiChagas.

Differential expression analysis

Statistical analyses were performed using R (3.6.2). The *DESeq2* package (v1.26.0) was used for data normalization and differential gene expression analyses (13), using shrinkage function to correct log2 fold change (log2(FC)). Benjamini-Hochberg method was applied to obtain False Discovery Rate (FDR) for each analysis. Genes with an FDR ≤ 0.05 and an absolute log2(FC) greater than 1.5 were considered as differentially expressed (DEG).

Functional enrichment

Gene Ontology Biological Process annotations enrichment was
performed using ClueGO cytoscape plugin and KEGG pathway
analysis was done with and GAGE (v2.36.0) (14) and pathview R
package (v1.26.0). ncRNAs enrichment was realized with three
databases: LncRNA2Target, LncTarD and LncRNADisease.

Evaluation of cell types in heart tissue

RNAseq deconvolution was performed using ADAPTS R package. Using data coming from heart tissue microarray and PBMC single-cell RNA-seq datasets, signature matrices were generated with ADAPTS. A Wilcoxon test (FDR<0.05) was applied between healthy control and CCC.

Tissue DNA methylation analysis

DNAs, extracted from whole tissue, were bisulfite converted and amplified with elongation of primers. Amplified DNAs were fragmented and hybridized in EPIC beads according to the protocol described by the manufacturer (Illumina, San Diego, California). Analysis of DNA methylation data was performed with the ChAMP package, using BMIQ for normalization and ComBat for batch-effect correction. Only genomic positions with an FDR<0.05 and a |Δβ|>0.2 were selected. A DMP (Differentially Methylated Position) is associated with a gene when the DMP is inside the gene body or in its promoter region (from gene TSS to 1.5kb upstream). The methylation data are available under the reference : (GEO accession: GSE191082).

Transcription factor binding site
characterization

An analysis of differentially methylated regions (DMR) was
done with the ChAMP package, using the DMRCate method,
with parameters lambda=400 and C=2. A DMR of interest was
defined as a region containing at least 1 DMP located in TSS
([TSS - 1500bp; TSS]), 1st Exon or 5'UTR region of DEGs; and
having an FDR ≤ 0.05. In order to identify transcription factor
binding sites (TFBS) affected by a difference in methylation, the
ReMap database was used (15). A total of 84 cell lines were
selected (Supplementary Table 2), containing immune and
heart-related cells, and including 151 transcription factors
(TF). First, the transcription factors specifically associated with
DMRs were identified with the OLOGRAM tool (16, 17) in a
pairwise analysis, meaning we identify the individual TFs
enriched with the DMRs. Only those with an FDR ≤ 0.05 were
retained. In a second step, we studied the combinations of those
selected TFs that were observed in the DMR by using the n-wise
overlap option of OLOGRAM (option -more-bed-multiple-
overlap, n ≤ 4). Finally, the known TFBS profiles of identified
transcription factor were retrieved from JASPAR database. The
location of each TFBS in DMR sequence was identified using
FIMO tool.

Blood DNA collection and DNA
methylation analysis

Blood (5 to 15 ml of blood) from 96 CCC patients (48 moderate
CCC (Left ventricular ejection fraction>40%) and 48 severe CCC
(left ventricular ejection fraction<40%)) and 48 asymptomatic
Chagas disease controls was also collected in EDTA tubes
(Supplementary Table 1). Genomic DNA was isolated using
standard salted methods and the methylation analysis was done
using the same protocol as tissue DNAs.

Results

Headings disregulated genes associated
to severe CCC

Gene expression analysis was conducted on left ventricular free wall myocardial tissue from 8 severe CCC patients and 6 healthy organ donors (see workflow: Figure 1). For each sample, we got between 40 and 75 million sequencing reads. Sequences were aligned to the human reference genome GRCh37/hg19. The average mappable rate of the raw reads reached 90% (+/- 2%). No parasite RNA was detected. This is not surprising, since in chronic and end stage patients, the parasite ARN is no longer detected. Gene expression data were obtained from 43533 transcripts. A small fraction of these transcripts (1407/43533 (3.23%)) were considered as differentially expressed between control and CCC (Supplementary Table 3), most part being up-regulated (Supplementary Figure 1A). A specific enrichment occurs in protein coding and non-coding genes, as miRNAs (Supplementary Table 4). PCA and HCA (Hierarchical Clustering Analysis) analysis confirmed that CCC myocardial

gene expression patterns were substantially different from
controls (Figure 2A and Supplementary Figure 2A). The sex
and the age of the patients have no impact on this clustering
(Supplementary Figures 2B, C).

Severe CCC is characterized by a strong
inflammatory signature not present
in DCM

To understand the pathogenic processes driving CCC, a
comparative study was conducted between CCC patients and
DCM patients. Among the 3188 genes are differentially
expressed in DCM, mostly down-regulated (Supplementary
Figure 1B), only 290 (9%) DEGs are in common with CCCs.
(Supplementary Table 5). This further emphasizes that the
mechanisms involved in CCC and DCM are not similar.

A functional analysis of the DEGs identified both in CCCs or
DCMs was conducted (Figure 3 and Supplementary Table 6).
Some biological processes are shared by both diseases, like
smooth muscle, ERK1/ERK2 cascade and ion transport.
Interestingly, calcium ions are particularly affected in CCC,
not in DCM. Regarding CCCs, DEGs are almost exclusively
specific to the immune response (innate or adaptive). Most of
enriched terms are related to T lymphocytes. More specifically,
the T CD8+ and T CD4+ are associated to CCC, as well as Th1
response. Besides T cells, other immune cells seem to act in the
pathogenic process of CCC, such as B cells, macrophages or NK
cells. The regulation of interleukin production is also affected,
included IL-1, IL-4, IL-6, IL-10 and IL-12. The chemokine
CXCL9 was the most highly expressed among the cytokines
(FC=78), followed by CCL19, IFN-gamma, CCL4, CXCL10,
CCL17, CCL22, CXCL11, IL-26, LTA, IL-16 and IL-18.
Together, these results provide an overview of the pathogenic
process associated with CCCs, which is mostly related to the
immune response. Furthermore, calcium ion transport seems to
be particularly important in CCCs, compared to DCMs.

Several non-coding RNA are specific to severe CCC

Non-coding RNAs are among the elements that can lead to
genetic dysregulation. As gene expression analysis was
performed by sequencing of total RNAs, we got information
on non-coding RNAs (lincRNA, miRNA, snRNA, snoRNA,
3'overlapping ncRNA). Among the 3777 non-coding elements
detected in our samples, 179, including 19 miRNAs and 145
lncRNAs; were differentially expressed. Those ncRNAs
(Supplementary Figure 3A) were enough to classify samples
according to their phenotype, demonstrating the importance of
these non-coding elements in chronic Chagas cardiomyopathy.
Only 6 had a known target (lncRNA-targeted gene: MIAT-miR-
<figure><img src="image_3.png" /><figcaption>FIGURE 1</figcaption></figure>

Workflow overview. Heart tissue RNAseq (orange) analysis was performed using classical steps: quality control, alignment, gene expression quantification and normalization. Then, three different analyses were done: deconvolution analysis, differentially expressed genes functional enrichment and non-coding RNAs characterization. Heart tissue (blue) and blood (green) methylation analysis followed the same first steps: quality control, normalization, batch effect correction, differential methylation position (DMP) test and DMPs associated genes functional enrichment. In tissue samples, a transcription factor binding site (TFBS) enrichment was carried out on differentially methylated regions (DMRs).

133a, RP11-276H19.1-GAS1, XIST-WNT1, MIR155HG-miR-155, LINC00707-ELAVL1 and KB-1732A1.1-E2F1). A similar analysis was performed on the ncRNAs associated to DCM (Supplementary Table 7 and Supplementary Figure 3B). 143/179 ncRNAs are specific to CCC (Supplementary Figure 3C).

## DNA methylation directly affect the expression of some DEGs

Given the importance of methylation in the regulation of genetic response (18), we also performed several DNA

<figure><img src="image_4.png" /><figcaption>FIGURE 2</figcaption></figure>

Analysis of samples clustering based on differentially expressed genes or differentially methylated CpG sites. Control samples identifiers are written in blue whereas case samples identifiers are written in red. (A) Hierarchical Clustering Analysis (HCA) performed on 6 control and 8 case samples, based on expression of 1409 differentially expressed genes. (B) Hierarchical Clustering Analysis (HCA) performed on the same samples as in A), based on methylation level of 16883 differentially methylated position.
<figure><img src="image_5.png" /><figcaption>FIGURE 3</figcaption></figure>

Gene Ontology Biological Process affected in severe CCC and/or DCM. Bubble chart of Gene Ontology Biological Process according to percent of severe CCC differentially expressed genes (DEG) and percent of total DEG (severe CCC + DCM) involved in each GO term. The size of each dot is associated to the enrichment of each GO term [-log₁₀(FDR)] and its color to disease specificity (from green for DCM to red for severe CCC).

methylation analyze in controls and CCC patients. Tissue sample DNA methylation analysis was conducted on the same samples as gene expression. Only 16883 CpGs (2.34%) were differentially methylated (FDR<0.05 and |Δ?|>0.2) (Supplementary Table 8) and were associated to 5814 genes. PCA and HCA analysis confirmed the impact of those DMP on CCC (Figure 2B and Supplementary Figure 2D). The sex and the age of the patients seems to have no impact on this clustering (Supplementary Figures 2E, F).

Among the 16883 identified DMPs, 996 DMPs are associated to 390 DEGs. Interestingly, the upstream region of those DEGs (from TSS-1500 to TSS, 1st exon and 5'UTR) are significantly enriched in down-methylated DMPs (FDR ≤ 0.05). Moreover, these down-methylated DMPs are, in 86% of the cases, associated with over-expressed DEGs. We retained these regions called "regulatory region" for further analysis.

## Identification of transcription factors potentially involved in severe CCC

Based on the 409 DMPs associated with DEG regulatory regions, we were able to define 92 regulatory DMRs (Supplementary Table 9). These DMRs span on average 245bp and are in the promoter regions of 89 DEGs. Three analyses were performed with OLOGRAM to determine whether the enrichment in TF is significantly different of which would be expected by chance. Two analyses were performed: (A) with the promoters of the DEGs and (B) with the DMRs alone. For both analyses,

enrichment was compared with all genomic promoters. (Figure 4A). The log2(FC)s of each TF in analysis (A) and (B) are significantly correlated (Spearman p-value ≤ 0.05), but the r2 is low (0.49) (Figure 4B) suggesting a different signal carried by the DMRs compared to all the promoters including the DMRs. Moreover, the log2(FC)s obtained in analysis B are significantly higher than the ones obtained in analysis A (Wilcoxon p-value=4.23E-07) (Figure 4C). These two analyses clearly show that there is a stronger enrichment of TFs in DMRs than in the promoter set. To confirm these results, a third analysis (C) was performed with the DMRs compared to the promoters of the DEGs containing these DMRs. The obtained distribution of the log2(FC) with this analysis showed two distinct peaks, one around 0 and another around 1.7 (Figure 4C), confirming that some TFs are specifically enriched in DMRs. A total of 30 TFs were found significantly associated to the DMRs in the analyses B and C. We also considered as a Cis-Regulatory Module (CRMs) the regions where at least 2 TFs bind to the genome according to ReMap. After data filtering and considering combinations of up to 4 TFs, we have identified 16 regions significantly associated with our DMRs, involving a total of 12 transcription factors (Supplementary Table 10). The top-regulators are BRD4, EED, BCLAF1, TBX21, RUNX3 and RUNX1.

## Immune, heart-relative or neurological processes affected by TFBS methylation

The 30 TFs previously identified are involved in several biological process, such as somatic recombination of
<figure><img src="image_6.png" /><figcaption>FIGURE 4</figcaption></figure>

Analysis of the relation between TFBS (Transcription Factor Binding Site). (A) Schematic illustration of the three approaches used in this analysis. Differentially methylated region (DMR) is highlighted in blue, gene regulatory region in green, and transcription factor (TF) in orange. Analysis 1: TFBS enrichment in regulatory region containing at least one DMR, compared to all genome regulatory region. For each gene, a regulatory region is defined as the region from TSS-1500 to first exon. Analysis 2: TFBS enrichment in DMR compared to all genome regulatory region. Analysis 3: TFBS enrichment in DMR compared to regulatory region containing at least one DMR. (B) Scatter plot of the log2(FC) obtained with the analysis 1 and 2 and Spearman correlation of these values. The fold change is computed according to the observed S value compared to obtained S value, S corresponding to the number of overlapping bases between TFBS and query region. (C) Distribution of the log2(FC) obtained with the 3 approaches.

immunoglobulin gene segments, regulation of cardiac muscle tissue growth or peripheral nervous system neuron development (Supplementary Table 11). Among the genes involved in the Th1/IFN-γ response, 19 genes are potentially targeted by 28 of the 30 TF previously identified, illustrating the important differential methylation of immune response-related genes in the pathogenic process associated with CCC. Seven TFs (BCLAF1, BRD4, CBFB, EED, PAX5, RUNX3 and TBX21) target at least 11/19 genes (Figure 5). A few of them are targeted by specific TFs (for example IFN-γ is targeted RUNX3+TBX21). Similar data were obtained for heart-relative or neurological process (Supplementary Figure 4).

## 5 TFBS identified in RUNX3 regulatory region

Of the 30 TFs of interest, 20 have at least one known motif in the Jaspar database, providing a total of 45 distinct motifs. After filtering predicted TFBS in our DMR overlapping at least one DMP, 423 TFBS have been identified, for all the 20 TFs (Supplementary Table 12). Interestingly, TBX21, RUNX3 and

EBF1 are the TFs whose binding motif appears to be affected by DNA methylation in the largest number of genes. Because these TFs are involved in many complexes, regulation of their binding may affect the binding of all TFs in the complexes.

Among the 25 genes with a low number of TFs binding in their promoter region (n ≤ 3), and thus being affected by specific TFs, 7 are targeted by TBX21 and 4 by RUNX3, showing again the importance of these TFs in CCC. Considering that RUNX3, a key regulator in CCCs, also has a DMR in its promoter region, further analysis was performed on this TF. On this 831 bp DMR, 5 TFBSs are present (Figure 6). This DMR is targeted by at least 6 of the following 7 TFs: RUNX3, PAX5, YY1, SP1, MAX, EBF1 and IRF4. SP1 and PAX5 seem to be the most affine with these sequences. PAX5 is always found associated to IRF4, suggesting an interaction between those 2 TFs.

## Immune cell type infiltration occurs in CCC heart tissue

Given the infiltration of immune cells in CCC myocardium, we characterized and quantified the proportions of these cell
<figure><img src="image_7.png" /><figcaption>FIGURE 5</figcaption></figure>

Predicted regulatory interaction in IFNy-Th1 pathway. Network composed by 19 genes involved in IFNy-Th1 pathway, and the top 7 TF predicted as targeting those 19 genes, according to *OLOGRAM* based on *ReMap* database. TF are written in blue in diamond, and genes in black in rectangle. Shapes borders are colored according to the fold change, from green to red.

types in our samples. First of all, immune cell signatures (19) showed in general a higher proportion of immune cells in CCCs compared to controls (Supplementary Figure 5A), such as activated NKs, and more interestingly T CD8, T Cell memory and T follicular helper, with a reduced proportion of M2 macrophages. Secondly, a human heart tissue (left ventricle) cell signature (20) showed that the CCCs had fewer cardiomyocytes and smooth muscle than the controls (Supplementary Figure 5B). Moreover, CCC myocardium had a higher proportion of macrophages, in line with the immune

cell infiltration in the cardiac tissues on CCC patients (Supplementary Table 13).

## Methylation sites in blood are associated to moderate or severe CCC

We also studied the DNA methylation in the blood of asymptomatic, moderate and severe CCC by hypothesizing that the blood data reflect the phenotype. We found 12624

<figure><img src="image_8.png" /><figcaption>FIGURE 6</figcaption></figure>

TFBS affected by methylation in RUNX3 regulatory region. Schematic representation of all TFBS found in RUNX3 regulatory region, using FIMO and Jaspar database. For each TFBS region, all the transcription factor predicted as affected by a differentiation of methylation in this region are rank by FIMO pvalue (***pvalue ≤ 0.001, **pvalue ≤ 0.01, *pvalue ≤ 0.05). The top-rank TF binding profile is shown, as well as the differentially methylated position in the TFBS.
DMPs between asymptomatic and severe CCC blood samples (FDR ≤ 0.05) (Supplementary Table 14). Despite the small variation in the level of DNA methylation detected in the blood (Δβ), the methylation of these 12624 DMPs was enough to separate controls from cases, either *via* PCA (Figure 7A) or HCA (Supplementary Figure 6A). Association was found in 6436 genes with at least one DMP, but only 139 genes are in common between the three analyses (RNA-seq in tissue and DNA methylation in tissue and blood).

6735 CpGs were found as DMPs between moderate and severe CCC (FDR<0.05) (Supplementary Table 15). They were

enough to discriminate samples according to the stage of the disease on a PCA (Figure 7B) or HCA (Supplementary Figure 6B). Only 470 DMPs were also identified as DMP in controls vs severe CCC blood methylation analysis, and 1750 genes out of 3911 (44.75%) are shared by both blood methylation analysis (non-significant enrichment). Interestingly, looking at the DNA methylation level of all DMPs found in blood (merge of the two previous analysis, n=18889) allowed us to distinguish the three groups of individuals, according to their phenotype (Figure 7C), revealing a gradient of methylation from controls to severe CCC through moderate CCC.

<figure><img src="image_9.png" /></figure>

FIGURE 7

Analysis of samples distribution in the space of differentially methylated CpG sites for asymptomatic, moderate CCC and severe CCC samples. (A) Scatterplot of the two principal components of a PCA executed in the space of the 12624 CpG positions differentially methylated (DMP) between 48 asymptomatic blood samples and 90 CCC blood samples. (B) Scatterplot of the two principal components of a PCA executed in the space of the 6735 DMPs between 47 moderate CCC blood samples and 43 severe CCC blood samples. (C) Scatterplot of the two principal components of a PCA executed in the space of the 18889 CpG positions (union of the two previous sets) for the three groups of samples.
<figure><img src="image_10.png" /><figcaption>FIGURE 8</figcaption></figure>

Comparison of differentially expressed genes, genes affected by methylation in tissue dataset and genes affected by methylation in blood dataset. (A) Venn diagram of top 1000 genes differentially expressed or methylated in previous tissue RNA-seq, tissue DNA methylation and blood DNA methylation analysis between control/asymptomatic and severe CCC samples. (B) Graph of the Gene ontology Biological Processes analysis of dysregulated element between control/asymptomatic and severe CCC. Nodes represents biological processes terms and are divided in 3 colors, according to the proportion of genes from RNA-seq (red), tissue methylation (blue) or blood methylation (green) analysis. Edges in the graph link GO terms having gene in common. 3 principal terms are highlighted in this synthesis. More precisely, several groups of gene ontology are enriched, involved in biological process related to: 1) lymphocyte activation; 2) Regulation of immune-system process; 3) Cytokine production; 4) Interferon gamma production; 5) Regulation of interleukin production; 6) Defense response; 7) System development; 8) Anatomical structure morphogenesis; 9) Metal ion transport; 10) Cation homeostasis.

## Nervous system related processes are strongly affected in moderate CCC

The general pattern detected on heart tissues and on blood are different and seemed to be tissue/fluid specific (Figure 8A). However, we conducted a Gene ontology analysis of the top 1000 genes of each analysis (Supplementary Table 16). 3 major biological processes are affected in our analyses: immune system, system development and ion transport (Figure 8B). They are shared by all three analyses, showing that although few genes are found in common, they are involved in common biological functions. Therefore, it seemed reasonable to analyze the methylation differences between moderate and severe CCC to understand the development of the disease (Supplementary Table 17). Unlike to the results found between controls and severe CCC, here genes are mostly involved in neurogenesis, cardiovascular system development or actin filament organization. These genes are associated with the immune response, notably in adaptive immune response and also with ion-related processes.

## Discussion

This study focused on the study of epigenetic regulation in Chagas disease, and its impact on the development of the disease. Based on RNAseq and methylation data, 1409 differentially expressed genes (DEGs) were identified, among which 89 have differentially methylated regions (DMRs) in their regulatory region. 30 transcription factors were identified as potentially affected by these methylation differences, suggesting their involvement in genetic deregulation. Furthermore, similar biological processes are affected by differences in methylation in cardiac tissue or blood. Therefore, the pathogenic process in patients with moderate CCC could be studied.

In a previous analysis, combining microarray and methylation data, we showed that patients with CCC had significant differences in gene expression and DNA methylation compared to healthy controls (9). DEGs with DMPs were predominantly associated with the immune response, but also with several biological processes such as arrhythmia, muscle contraction, fibrosis and mitochondrial function. Here, we have set up a more advanced analysis,
allowing us to have an in-depth analysis of genomic
dysregulation. To do so, we were interested in both DNA
methylation in order to identify transcription factors involved
in the pathogenic process and in non-coding RNAs. Indeed,
non-coding RNA, notably lncRNA and miRNA, are known to be
involved in many of cardiovascular diseases (21, 22). The
presented results extend the list of miRNAs associated to
CCC, and not differentially expressed in DCM (10, 21, 23–27).
Among the 19 miRNAs identified in this study, 3 have already
been associated with severe CCC: miR-223, miR-208 and miR-
151 (6). The involvement of the long non-coding RNA MIAT,
previously associated to CCC (11), has also been confirmed. It
acts as a sponge of miRNA-133 in breast cancer, dysregulated in
CCC (10), and down-regulated in patients with heart
failure (28).

Three distinct biological process were associated to CCC,
either we look at gene dysregulation or methylation, in heart
tissue or blood: immune response, ion transport and nervous
system. Although ion transport and nervous system were also
partially associated to DCM, immune response remains specific
to CCC. Moreover, the genes affected in those pathways were not
the same between these diseases, illustrating a specific response
in CCC. For example, several genes associated to ion transport,
and more precisely with potassium voltage-gated ion channel,
like KCNA2, KCNA5, KCNAB2, KCNB2, KCNC2, KCNG3 and
KCNN4, were found to be differentially expressed and/or
methylated in CCC, and not in DCM. Of interest, while
KCNB2, KCNC2 and KCNG3 are mainly expressed in
neurons, KCNA5 is expressed in heart muscle and dendritic
cells, while KCNA2, KCNAB2 are expressed in neurons and
immune cells, indicating that potassium channels of neuronal,
cardiomyocyte and inflammatory cells are modulated in CCC
heart tissue. Dysregulation of potassium channel genes were
reported in heart of 36 *T.cruzi* infected mice (21) and 25 severe
CCC heart (9). Dampening of calcium and potassium ion
channels in mouse heart tissue led to a reduced Ca2+ release
and prolongation of action potential (29). TNF-α may amplify
this dysfunction by inducing nitric oxide synthase (NOS2) and
oxidant species, which promotes electrophysiological changes in
rat ventricular myocyte (30). KCNN4 (KCa3.1), differentially
expressed in CCC (not in DCM) and containing DMP in its
promoter, acts as a regulator of membrane potential in T cells.
After antigen recognition by the T cell repertoire, the Ca2+
enters in the cytosol and sequentially activate KCa3.1 and Kv1.3
(KCNA3), causing membrane depolarization (31). This calcium,
present in cytosol, will activate the NFAT protein, which
regulate genes involving in T cell activation (32). Moreover,
high levels of Kv1.3 were found in multiple autoimmune
diseases, such as multiple sclerosis or diabetes (33–35). In our
data, these two potassium channels are up-regulated, and
KCa3.1 seems to be targeted by RUNX3. The potential
biomarker for heart disease Galectin-3 (Gal-3), upregulating

the expression and activity of KCa3.1 channel in inflammatory
cells and fibroblasts. Upregulated KCa3.1 facilitates
inflammatory cell infiltration into the myocardium and
fibroblast differentiation into activated form. Recently, it was
shown that mice treated with TRAM-34, a KCa3.1 channel-
specific inhibitor, either for 1- or 2-month period effectively
reduced collagen deposition (36). Moreover, Gang et al. had
shown that KCa3.1 inhibition by TRAM-34 therapy attenuated
the increased inflammatory cell infiltration. Rezende de Castro et
al. (37) studied gene expression profiling in acutely *T.cruzi*
infected mice (15-day post-infection) and have found enriched
pathways related to immunity and Th1 T cell immunity, cardiac
conduction including potassium channels, protein synthesis and
mitochondrial genes. Even though acute infection by *T.cruzi*
(where parasites are very numerous in the myocardium) is not a
perfect match for CCC, where parasites are scarce or absent from
heart tissue, modulation of inflammatory cell and potassium
channel gene expression profiles are similar in both situations.

On the other hand, our study underlined that several genes
associated with moderate or severe CCC are involved in the
nervous system. This enrichment is even stronger in moderate
CCCs. Actually, the loss of neuron cells is a well-known
phenomenon in digestive forms of Chagas disease (38, 39). In
human hearts with dilated cardiomyopathy, the number of
neuron cells is significantly reduced compared to controls.
This neuronal depopulation is even more important in CCC
(40), and during the acute phase in the mouse model (41).
Similarly, a study showed that acute phase *T.cruzi* infected dogs
displayed a rarefaction of the noradrenergic and acetylcholine
nerve terminals accompanied by myocarditis, and the ventricles
sympathetic denervation was present when the inflammatory
process was moderate to intense (42). Moreover, in the rat
model, moderate myocarditis lasting for two weeks caused
complete denervation (43). A more recent study demonstrated
that knockdown of acetylcholine in mice increased the Th1
response and clearance of *T.cruzi* parasitism in blood and tissue,
but worsens the cardiac lesions and inflammatory infiltration
(44). In the continuity of these observations, the increase in the
amount of acetylcholine was associated with reduction of heart
weight, inflammatory infiltration, and the fibrosis area,
suggesting a reversing of cardiac hypertrophy (44). Moreover,
macrophages, Th1, CD4 and B cells express adrenergic receptors
(45-47). Their stimulation induces an increase of cAMP, which
inhibits NF-kB activation, leading to the suppression of type 1
pro-inflammatory cytokines and promoting the production of
type 2 anti-inflammatory cytokines, such as IL10. This cytokine
inhibits the antigen presenting capacity of macrophages and
dendritic cells, and thus the differentiation of CD4 T cells to Th1
(48). Finally, circulating antibodies binding acetylcholine and
norepinephrine receptors have been found in Chagas patient
serum, suggesting an autoimmune response (49), and correlated
with the previous study, inducing the lack of neurotransmitters,
and then the over production of Th1 cells. In our data, the genes related to acetylcholine production, or acetylcholine transporter are not differentially methylated or expressed in tissue samples according to fold change cut-off but present an FDR<0.05. In blood methylation samples, ACHE (acetylcholine production), and CHRNA3, CHRNA4 and CHRNA7 (acetylcholine receptors) genes have differentially methylated positions in the promoter or body. While CHRNA4 is mainly expressed in neurons, ACHE is found in neurons and cardiac/skeletal muscle, CHRNA7 is mainly expressed in neurons, cardiac/skeletal muscle and immune cells, and CHRNA3 is found in neurons, and thymus.

Both potassium voltage-gated ion channel and nervous system identified in the current and previous studies seem to be linked to immune response, and more precisely T-cell related process. Moreover, in our data, the immune response was strongly stimulated, especially the activation of T cells even in the absence of the parasite. This inflammatory infiltrate was already reported elsewhere (50) and is mainly composed of Th1 lymphocytes, macrophages, and NK-cells. In this work, we performed a deconvolution analysis on our heart tissue collection, and we confirmed the content of this infiltrate. Our group, among others, had already shown that the T-cell infiltrating heart tissue strongly produced IFN-γ and TNF-α (4). In parallel, lower quantities of IL-2, IL-4, IL-6 and IL-10 were detected in CCC heart tissue (51). Our results are consistent with current knowledge of the pathology, with high expression of genes involved in IFN-γ and cytokine production. According to Gene Ontology Biological Process enrichment, genes affected in CCC are also involved in interleukin production, including IL-2, IL-4 and IL-6. IFN-γ, which has been described simultaneously as a pathogen resistance and a disease tolerance gene is also acting as an upstream regulator (52). Indeed, IFN-γ stimulates the inflammatory response indirectly via the NF-κB pathway and activate the production of ROS and NOS, which, in an excessive quantity, have also deleterious effect on mitochondria and cardiomyocytes (5). Interestingly, IFN-γ, with IFN-β and TNF-α (53), induced expression of miR-155 (53). In our data, MIR155HG, coding for this miRNA, is up-regulated. miR-155 is also up-regulated in viral myocarditis; where it is expressed by infiltrating immune cells, and seems to be involved in TNF-α, IFN-γ and IL-6 production, as well as immune cell infiltration (54). The lack of this microRNA seems to decrease IFN-γ and TNF-α in the acute stage of Chagas cardiomyopathy in mice heart tissue (21). Moreover, we found a DMR in IFN-γ promoter region, targeted TBX21. According to Ologram, RUNX3 could also fix this DMR, but its TFBS wasn't found in this DMR, as described in JASPAR database. Those two transcriptions factors are involved in Th1 differentiation, as well as GATA3 (55, 56). According to our analysis, the micro-RNA miR-142, associated to Th1 differentiation (57) in neuronal autoimmune disease,

potentially targets RUNX3 and TBX21. In Chagas disease, TBX21 and IFN-γ expression are correlated with the left ventricular dilation, and the ratio between TBX21 and GATA3 expression is significantly higher in CCC than in non-inflammatory cardiomyopathy (58), which were also confirmed in our data in both control to CCC or DCM comparisons. Moreover, RUNX3 overexpression has been associated to the methylation of its promoter in CCC (9), as well as in our current analysis. In total, RUNX3 and TBX21 targets 29 genes, including 14 in common (AIM2, ARHGAP30, BATF, C16orf54, CCR5, CYTIP, DENND2D, DOK2, FGR, MIR142, PTPN22, TRAF1, TRAF3IP3 and WDFY4). Moreover, RUNX3 is targeted by 7 transcription factors: EBF1, IRF4, MAX, PAX5, RUNX3, SP1 and YY1.

We also found that XIST is one of the tops up-regulated lncRNA in Chagas disease. It is associated with the WNT1 gene, belonging to the Wnt family, but because of the wide sex dispersion in our dataset, we cannot conclude the direct involvement of this lncRNA in CCC. In our data, WNT1, as well as WNT10A and WNT10B are up-regulated in severe CCC. The Wnt pathway is involved in the differentiation of Th2 cells (59) and its inhibition in acute Chagas disease stage decrease the Th2 response (60) and increase inflammatory response, controlling the parasite (61). Studies have demonstrated that Wnt activation is related to pathological stages including inflammation, angiogenesis, and fibrosis and aberrant expression is associated with cardiovascular diseases (61, 62). Indeed, Analysis of the expression of Wnt proteins indicated that Wnt-2, Wnt-4, Wnt-10b, and Wnt-11 were significantly upregulated 5 days after myocardial infarction (63). Studies confirmed the interactions between the Wnt pathway and TGF-β signalling (64–66). TGF-β receptor overexpression has already been observed in acute phase of CCC (67). It has several role in CCC development, including parasitic invasion, inflammation, immune response, heart fibrosis and heart conduction (68). Our results had also shown the potential implication of NOTCH1 (downregulated and targeting DEGs with DMRs in their regulatory regions) in the genetic dysregulation in severe CCC. Activation of Notch signalling limits the range of cardiac damage by the improving of angiogenesis (69–71), cardiac regeneration and cardio protection (72), and reducing fibrosis (73), apoptosis (74), and oxidative stress (75).

Few studies have linked Notch signaling to immune response and parasitic infections. Tu et al. has shown that in *Trichuris muris* infection, a deficiency of Notch signaling in T cells led to a failure in initiating the Th2 response (76). It suggests that Notch signaling influences the Th2 profile and alters immune responses against parasites. Similarly, during Leishmania major infection, the Th1 response was induced in deficient mice, which presented high levels of IFN-γ that led to infection control (76). So, we can raise the hypothesis that a
down expression of NOTCH1 in CCC patients promote the Th1 response associated to severe cardiomyopathy. To support this hypothesis, Guzmán-Rivera et al. had treated Chagas infected mice with simvastatin (77). Simvastatin activates the Notch 1 pathway in the hearts of *T.cruzi* infected mice and decreases the cellular infiltrate, inflammatory cytokines and prevents the increase in collagen deposition in cardiac tissue.

All the results obtained in our study converge towards a combined involvement of processes related to the immune response, ion transport, cardiac contraction and the nervous system. In particular, the nervous system appears to be strongly impacted between moderate and severe CCC, and the potassium-related process specific to CCC compared to DCM. Gene expression analysis alone has revealed some non-coding elements but has not provided so much new information about the disease. The inclusion of methylation put forward less obvious biological processes. Thus, most of the identified genes (differentially expressed and/or methylated) are generally involved in several of these processes, highlighting links between them. More precisely, all the previously described biological process seems to be linked to the immune response, and notably to the Th1 response, including IFN-γ and RUNX3. These results, combined with those obtained in previous analyses of CCC (9, 78), confirm the importance of DNA methylation in the development of CCC.

## Data availability statement

The datasets presented in this study can be found in online repositories. The names of the repository/repositories and accession number(s) can be found in the article/Supplementary Material.

## Ethics statement

The protocol was approved by the institutional review boards of the University of São Paulo School of Medicine and INSERM (French National Institute of Health and Medical Research). Written informed consent was obtained from all patients. All experimental methods comply with the Helsinki Declaration.

## Author contributions

All authors listed have made a substantial, direct, and intellectual contribution to the work and approved it for publication. Study design: PB, JK, LS, ECN, CC. Phenotype characterization: BMI, CM, RHBS, SS, ANS, PP, AIF, EAB, CWP, BS, FCD, MFS, FAG, JAMN, AF, SS, GDLP, FB, PB, HTLW, AS, MM, MHH, EAD, ACP, VRJ, Experimental

analysis: PB, LL, AFF, JPSN, PCT, LRPF, AK, SC, DDSC, RCFZ, VOCTRRA. Statistical analysis: PB, QF, DP, LS, ECN, CC. Manuscript preparation: PB, LS, ECN, CC.

## Funding

This work was supported by the Institut National de la Santé et de la Recherche Médicale (INSERM); the Aix-Marseille University (grant number: AMIDEX "International_2018" MITOMUTCHAGAS); the French Agency for Research (Agence Nationale de la Recherche-ANR (grant numbers: "Br-Fr-Chagas", "landscardio"); the CNPq (Brazilian Council for Scientific and Technological Development); and the FAPESP (São Paulo State Research Funding Agency Brazil (grant numbers: 2013/50302-3, 2014/50890-5); the National Institutes of Health/USA (grant numbers: 2 P50 AI098461-02 and 2U19AI098461-06). This work was founded by the Inserm Cross-Cutting Project GOLD. This project has received funding from the Excellence Initiative of Aix-Marseille University - A*Midex a French "Investissements d'Avenir programme"- Institute MarMaRa AMX-19-IET-007. JPSN was a recipient of a MarMaRa fellowship. EC-N and JK, are recipients of productivity awards by CNPq. The funders did not play any role in the study design, data collection and analysis, decision to publish, or preparation of the manuscript.

## Acknowledgments

Center de Calcul Intensif d'Aix-Marseille is acknowledged for granting access to its high performance computing resources. Authors thanks Delphine Potier, Pierre Milpied, Benoit Ballester for helpful discussions and comments.

## Conflict of interest

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

## Publisher's note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.
# Supplementary material

The Supplementary Material for this article can be found online at: https://www.frontiersin.org/articles/10.3389/fimmu.2022.958200/full#supplementary-material

## SUPPLEMENTARY TABLE 1

Biological samples included in this study.

## SUPPLEMENTARY TABLE 2

Cell lines description.

## SUPPLEMENTARY TABLE 3

List of unique differentially expressed genes identified by RNA-seq between 8 end stage CCC heart tissue samples and 6 heart tissue samples obtained from organ donors.

## SUPPLEMENTARY TABLE 4

Statistics on coding sequences detected by RNA-seq and on differentially expressed genes.

## SUPPLEMENTARY TABLE 5

List of unique differentially expressed genes identified by RNA-seq between 8 DCM heart tissue samples and 6 heart tissue samples obtained from organ donors.

## SUPPLEMENTARY TABLE 6

Gene ontology analysis based on differentially expressed genes between control and severe CCC and/or between control and DCM.

## SUPPLEMENTARY TABLE 7

List of differentially expressed ncRNAs between control and severe CCC, or between control and dilated cardiomyopathies.

## SUPPLEMENTARY TABLE 8

List of the Differentially Methylated CpGs on heart tissues samples (controls versus CCC).

## SUPPLEMENTARY TABLE 9

List of the regulatory DMRs associated to the 89 DEGs.

## SUPPLEMENTARY TABLE 10

List of transcription factor and transcription factor complexes testing against our DMRs.

## SUPPLEMENTARY TABLE 11

Gene ontology analysis of the TFs binding our DMRs.

## SUPPLEMENTARY TABLE 12

For each DMR, list of predicted Transcription Factor Binding Site (TFBS) and their associated Transcription Factor (TF).

## SUPPLEMENTARY TABLE 13

Cell type proportions in RNA-seq by comparison to cell type signatures.

## SUPPLEMENTARY TABLE 14

List of the Differentially Methylated CpGs between blood asymptomatic samples and blood CCC samples.

## SUPPLEMENTARY TABLE 15

List of the Differentially Methylated CpGs between blood moderate CCC samples and blood severe CCC samples.

## SUPPLEMENTARY TABLE 16

Gene ontology analysis based on differentially expressed genes between control and severe CCC and/or genes affected by at least one differentially methylated CpGs between tissue control and severe CCC and/or genes affected by at least one differentially methylated CpGs between blood asymptomatic and severe CCC samples.

## SUPPLEMENTARY TABLE 17

Gene ontology analysis based on genes affected by at least one differentially methylated CpGs between blood moderate CCC samples and blood severe CCC samples.

## SUPPLEMENTARY FIGURE 1

Volcanopots of differential expression testing for CCC and DCM. Volcanoplot showing the difference of gene expression between (A) controls and CCCs or (B) controls and DCMs. On the x-axis is represented the log2(FC) and on the y-axis the -log10(adjusted pvalue). Overexpressed DEGs are in red, and underexpressed in green.

## SUPPLEMENTARY FIGURE 2

Analysis of samples distribution in the space of differentially expressed genes or differentially methylated CpG sites between control and severe CCC. Age and sex impact on gene expression or on methylation. (A) Scatterplot of the two first principal component of a PCA of 6 Control and 8 Case samples executed in the space of the 1409 differentially expressed genes between the two conditions. (B) Scatterplot of the two first principal component of a PCA of 6 Control and 8 Case samples executed in the space of the 1409 differentially expressed genes between the two conditions colored by sex (blue: male, pink: female). (C) Scatterplot of the two first principal component of a PCA of 6 Control and 8 Case samples executed in the space of the 1409 differentially expressed genes between the two conditions colored by age (from grey to blue). (D) Scatterplot of the two first principal component of a PCA of 6 Control and 8 Case samples executed in the space of the 16883 differentially methylated CpG sites between the two conditions. (E) Scatterplot of the two first principal component of a PCA of 6 Control and 8 Case samples executed in the space of the 16883 differentially methylated CpG sites between the two conditions colored by sex (blue: male, pink: female). (F) Scatterplot of the two first principal component of a PCA of 6 Control and 8 Case samples executed in the space of the 16883 differentially methylated CpG sites between the two conditions colored by age (from grey to blue).

## SUPPLEMENTARY FIGURE 3

ncRNA analysis in severe CCC and DCM. Control samples identifiers are written in blue, severe CCC samples identifiers in red and DCM samples in green. (A) Hierarchical Clustering Analysis (HCA) performed on 6 control and 8 severe CCC samples, based on expression of 179 differentially expressed ncRNAs. (B) Hierarchical Clustering Analysis (HCA) performed on 6 control and 8 DCM samples, based on expression of 327 differentially expressed ncRNAs. (C) Venn diagram of shared differentially expressed ncRNAs between severe CCC and DCM.

## SUPPLEMENTARY FIGURE 4

Predicted regulatory interaction in cardiac muscular or nervous system process. Network composed by 6 transcription factors (TF) involved in cardiac muscular and/or nervous system process, and their 68 targeted genes, predicted by OLOGRAM according to ReMap database. TF are written in blue in diamond, and genes in black in rectangle. Shapes borders are colored according to the fold change, from green to red.

## SUPPLEMENTARY FIGURE 5

Estimation of cell proportion in control and severe CCC heart tissue. Deconvolution of the RNA-seq bulk gene expressions of 6 control and 8 severe CCC samples to infer the proportion of cells in the samples. The * represent cell types whose proportion is significantly different (Wilcoxon test, FDR <0.05) between controls and cases. (A) Deconvolution using cell type signature with 22 immunological cell types (LM22 signature matrix). (B) Deconvolution using cell type signature with 5 left ventricle related cell types.

## SUPPLEMENTARY FIGURE 6

Analysis of samples clustering based on differentially methylated CpG sites in blood samples. Asymptomatic samples identifiers are written in blue, moderate CCC in orange and severe CCC in red. (A) Hierarchical Clustering Analysis (HCA) performed on 48 asymptomatic and 90 severe CCC samples, based on expression of 12624 differentially methylated position. (B) Hierarchical Clustering Analysis (HCA) performed on 47 moderate CCC and 43 severe CCC samples, based on methylation level of 6735 differentially methylated position.
## References

1. Pérez-Molina JA, Molina I. Chagas disease. *Lancet* (2018) 391(10115):82–94. doi: 10.1016/S0140-6736(17)31612-4

2. Freitas HFG, Chizzola PR, Paes ÂT, Lima ACP, Mansur AJ. Risk stratification in a Brazilian hospital-based cohort of 1220 outpatients with heart failure: role of chagas' heart disease. *Int J Cardiol* (2005) 102(2):239–47. doi: 10.1016/j.ijcard.2004.05.025

3. Morillo CA, Marin-Neto JA, Ave zum A, Sosa-Estani S, Rassi A, Rosas F, et al. Randomized trial of benznidazole for chronic chagas' cardiomyopathy. *New Engl J Med* (2015) 373(14):1295–306. doi: 10.1056/NEJMoa1507574

4. Abel LC, Rizzo LV, Ianni B, Albuquerque F, Bacal F, Carrara D, et al. Chronic chagas' disease cardiomyopathy patients display an increased IFN-gamma response to trypanosoma cruzi infection. *J Autoimmun* (2001) 17(1):99–107. doi: 10.1006/jaut.2001.0523

5. Cunha-Neto E, Dzau VJ, Allen PD, Stamatiou D, Benvenutti L, Higuchi ML, et al. Cardiac gene expression profiling provides evidence for cytokinopathy as a molecular mechanism in chagas' disease cardiomyopathy. *Am J Pathol* (2005) 167 (2):305–13. doi: 10.1016/S0002-9440(10)62976-8

6. Laugier L, Ferreira LRP, Ferreira FM, Cabantous S, Frade AF, Nunes JP, et al. miRNAs may play a major role in the control of gene expression in key pathobiological processes in chagas disease cardiomyopathy. *PLoS Negl Trop Diseases* (2020) 14(12):e0008889. doi: 10.1371/journal.pntd.0008889

7. Jo BS, Koh IU, Bae JB, Yu HY, Jeon ES, Lee HY, et al. Methylome analysis reveals alterations in DNA methylation in the regulatory regions of left ventricle development genes in human dilated cardiomyopathy. *Genomics* (2016) 108(2):84–92. doi: 10.1016/j.ygeno.2016.07.001

8. Haas J, Frese KS, Park YJ, Keller A, Vogel B, Lindroth AM, et al. Alterations in cardiac DNA methylation in human dilated cardiomyopathy. *EMBO Mol Med* (2013) 5(3):413–29. doi: 10.1002/emmm.201201553

9. Laugier L, Frade AF, Ferreira FM, Baron MA, Teixeira PC, Cabantous S, et al. Whole-genome cardiac DNA methylation fingerprint and gene expression analysis provide new insights in the pathogenesis of chronic chagas disease cardiomyopathy. *Clin Infect Dis* (2017) 65(7):1103–11. doi: 10.1093/cid/cix506

10. Ferreira LRP, Frade AF, Santos RHB, Teixeira PC, Baron MA, Navarro IC, et al. MicroRNAs miR-1, miR-133a, miR-133b, miR-208a and miR-208b are dysregulated in chronic chagas disease cardiomyopathy. *Int J Cardiol* (2014) 175 (3):409–17. doi: 10.1016/j.ijcard.2014.05.019

11. Frade AF, Laugier L, Ferreira LRP, Baron MA, Benvenuti LA, Teixeira PC, et al. Myocardial infarction-associated transcript, a long noncoding RNA, is overexpressed during dilated cardiomyopathy due to chronic chagas disease. *J Infect Dis* (2016) 214(1):161–5. doi: 10.1093/infdis/jiw095

12. Frade AF, Teixeira PC, Ianni BM, Pissetti CW, Saba B, Wang LHT, et al. Polymorphism in the alpha cardiac muscle actin 1 gene is associated to susceptibility to chronic inflammatory cardiomyopathy. *PLoS One* (2013) 8(12): e83446. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3868584/. doi: 10.1371/journal.pone.0083446

13. Love MI, Huber W, Anders S. Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2. *Genome Biol* (2014) 15(12):550. doi: 10.1186/s13059-014-0550-8

14. Luo W, Friedman MS, Shedden K, Hankenson KD, Woolf PJ. GAGE: generally applicable gene set enrichment for pathway analysis. *BMC Bioinf* (2009) 10(1):161. doi: 10.1186/1471-2105-10-161

15. Chêneby J, Gheorghe M, Artufel M, Mathelier A, Ballester B. ReMap 2018: an updated atlas of regulatory regions from an integrative analysis of DNA-binding ChIP-seq experiments. *Nucleic Acids Res* (2018) 46(D1):D267–75. doi: 10.1093/nar/gkx1092

16. Ferré Q, Charbonnier G, Sadouni N, Lopez F, Kermezli Y, Spicuglia S, et al. OLOGRAM: Determining significance of total overlap length between genomic regions sets. *Bioinformatics* (2019), 36(6):btz810. doi: 10.1093/bioinformatics/btz810

17. Ferré Q, Capponi C, Puthier D. OLOGRAM-MODL: mining enriched n-wise combinations of genomic features with Monte Carlo and dictionary learning. *NAR Genomics Bioinf* (2021) 3(4):lqab114. doi: 10.1093/nargab/lqab114

18. Razin A, Cedar H. DNA Methylation and gene expression. *Microbiol Rev* (1991) 55(3):451–8. doi: 10.1128/mr.55.3.451-458.1991

19. Newman AM, Liu CL, Green MR, Gentles AJ, Feng W, Xu Y, et al. Robust enumeration of cell subsets from tissue expression profiles. *Nat Methods* (2015) 12 (5):453–7. doi: 10.1038/nmeth.3337

20. Wang L, Yu P, Zhou B, Song J, Li Z, Zhang M, et al. Single-cell reconstruction of the adult human heart during heart failure and recovery reveals the cellular landscape underlying cardiac function. *Nat Cell Biol* (2020) 22(1):108–19. doi: 10.1038/s41556-019-0446-7

21. Navarro IC, Ferreira FM, Nakaya HI, Baron MA, Vilar-Pereira G, Pereira IR, et al. MicroRNA transcriptome profiling in heart of trypanosoma cruzi-infected mice: Parasitological and cardiological outcomes. *PLoS Negl Trop Dis* (2015) 9(6): e0003828. doi: 10.1371/journal.pntd.0003828

22. Hobuß L, Bär C, Thum T. Long non-coding RNAs: At the heart of cardiac dysfunction? *Front Physiol* (2019) 10:30/full. doi: 10.3389/fphys.2019.00030/full

23. Ballinas-Verdugo MA, Jiménez-Ortega RF, Martínez-Martínez E, Rivas N, Contreras-López EA, Carbó R, et al. Circulating miR-146a as a possible candidate biomarker in the indeterminate phase of chagas disease. *Biol Res* (2021) 54(1):21. doi: 10.1186/s40659-021-00345-3

24. Ferreira LRP, Ferreira FM, Laugier L, Cabantous S, Navarro IC, da Silva Cândido D, et al. Integration of miRNA and gene expression profiles suggest a role for miRNAs in the pathobiological processes of acute trypanosoma cruzi infection. *Sci Rep* (2017) 7(1):17990. doi: 10.1038/s41598-017-18080-9

25. Jha BK, Varikuti S, Seidler GR, Volpedo G, Satoskar AR, McGwire BS. MicroRNA-155 deficiency exacerbates trypanosoma cruzi infection. *Infection Immun* (2020) 88(7):e00948-19. doi: 10.1128/IAI.00948-19

26. Nonaka CKV, Macêdo CT, Cavalcante BRR, de Alcântara AC, DN S, Bezerra M da R, et al. Circulating miRNAs as potential biomarkers associated with cardiac remodeling and fibrosis in chagas disease cardiomyopathy. *Int J Mol Sci* (2019) 20(16):E4064. doi: 10.3390/ijms20164064

27. Nonaka CKV, Sampaio GL, Silva KN, Khouri R, Macedo CTChagas Translational Research Consortium null, et al. Therapeutic miR-21 silencing reduces cardiac fibrosis and modulates inflammatory response in chronic chagas disease. *Int J Mol Sci* (2021) 22(7):3307. doi: 10.3390/ijms22073307

28. Vogel B, Keller A, Frese KS, Leidinger P, Sedaghat-Hamedani F, Kayvanpour E, et al. Multivariate miRNA signatures as biomarkers for non-ischaemic systolic heart failure. *Eur Heart J* (2013) 34(36):2812–22. doi: 10.1093/eurheartj/eht256

29. Roman-Campos D, Sales-Júnior P, Duarte HL, Gomes ER, Guatimosim S, Ropert C, et al. Cardiomyocyte dysfunction during the chronic phase of chagas disease. *Mem Inst Oswaldo Cruz* (2013) 108(2):243–5. doi: 10.1590/0074-0276108022013019

30. Fernández-Velasco M, Ruiz-Hurtado G, Hurtado O, Moro MA, Delgado C. TNF-alpha downregulates transient outward potassium current in rat ventricular myocytes through iNOS overexpression and oxidant species generation. *Am J Physiol Heart Circ Physiol* (2007) 293(1):H238–245. doi: 10.1152/ajpheart.01122.2006

31. Lewis RS. Calcium signaling mechanisms in T lymphocytes. *Annu Rev Immunol* (2001) 19:497–521. doi: 10.1146/annurev.immunol.19.1.497

32. Hogan PG. Calcium-NFAT transcriptional signalling in T cell activation and T cell exhaustion. *Cell Calcium* (2017) 63:66–9. doi: 10.1016/j.ceca.2017.01.014

33. Beeton C, Wulff H, Barbara J, Clot-Faybesse O, Pennington M, Bernard D, et al. Selective blockade of T lymphocyte k(+) channels ameliorates experimental autoimmune encephalomyelitis, a model for multiple sclerosis. *Proc Natl Acad Sci USA* (2001) 98(24):13942–7. doi: 10.1073/pnas.241497298

34. Beeton C, Wulff H, Standifer NE, Azam P, Mullen KM, Pennington MW, et al. Kv1.3 channels are a therapeutic target for T cell-mediated autoimmune diseases. *Proc Natl Acad Sci USA* (2006) 103(46):17414–9. doi: 10.1073/pnas.0605136103

35. Rus H, Pardo CA, Hu L, Darrah E, Cudrici C, Niculescu T, et al. The voltage-gated potassium channel Kv1.3 is highly expressed on inflammatory infiltrates in multiple sclerosis brain. *Proc Natl Acad Sci USA* (2005) 102 (31):11094–9. doi: 10.1073/pnas.0501770102

36. She G, Hou MC, Zhang Y, Zhang Y, Wang Y, Wang HF, et al. Gal-3 (Galectin-3) and KCa3.1 mediate heterogeneous cell coupling and myocardial fibrogenesis driven by βAR (β-adrenoceptor) activation. *Hypertension* (2020) 75 (2):393–404. doi: 10.1161/HYPERTENSIONAHA.119.13696

37. de Castro TBR, Canesso MCC, Boroni M, Chame DF, Souza D de L, de Toledo NE, et al. Differential modulation of mouse heart gene expression by infection with two trypanosoma cruzi strains: A transcriptome analysis. *Front Genet* (2020) 11:1031. doi: 10.3389/fgene.2020.01031

38. Köberle F. The causation and importance of nervous lesions in American trypanosomiasis. *Bull World Health Organ* (1970) 42(5):739–43. doi: 10.1055/s-2008-1041127

39. Villanueva MS. Trypanosomiasis of the central nervous system. *Semin Neurol* (1993) 13(2):209–18. doi: 10.1055/s-2008-1041127

40. Amorim DS, Olsen EG. Assessment of heart neurons in dilated (congestive) cardiomyopathy. *Br Heart J* (1982) 47(1):11–8. doi: 10.1136/hrt.47.1.11

41. de Souza MM, Andrade SG, Barbosa AA, Macedo Santos RT, Alves VA, Andrade ZA. Trypanosoma cruzi strains and autonomic nervous system pathology
in experimental chagas disease. *Mem Inst Oswaldo Cruz* (1996) 91(2):217-24. doi: 10.1590/S0074-02761996000200018

42. Machado CR, Caliari MV, de Lana M, Tafuri WL. Heart autonomic innervation during the acute phase of experimental American trypanosomiasis in the dog. *Am J Trop Med Hygiene* (1998) 59(3):492-6. doi: 10.4269/ajtmh.1998.59.492

43. Machado CRS, Ribeiro ALP, Machado CRS, Ribeiro ALP. Experimental american trypananiasis in rats: sympathetic denervation, parasitism and inflammatory process. *Memórias do Instituto Oswaldo Cruz* (1989) 84(4):549-56. doi: 10.1590/S0074-02761989000400013

44. Machado MPR, Rocha AM, de Oliveira LF, de Cuba MB, de Loss IO, Castellano LR, et al. Autonomic nervous system modulation affects the inflammatory immune response in mice with acute chagas disease. *Exp Physiol* (2012) 97(11):1186-202. doi: 10.1113/exphysiol.2012.066431

45. Elenkov IJ, Wilder RL, Chrousos GP, Vizi ES. The sympathetic nerve-an integrative interface between two supersystems: the brain and the immune system. *Pharmacol Rev* (2000) 52(4):595-638. doi: 10.1189/jlb.J1105625

46. Kin NW, Sanders VM. It takes nerve to tell T and b cells what to do. *J Leukoc Biol* (2006) 79(6):1093-104. doi: 10.1189/jlb.J1105625

47. Kohm AP, Sanders VM. Norepinephrine and beta 2-adrenergic receptor stimulation regulate CD4+ T and b lymphocyte function *in vitro* and *in vivo*. *Pharmacol Rev* (2001) 53(4):487-525. doi: 10.1038/nri1810

48. Sternberg EM. Neural regulation of innate immunity: a coordinated nonspecific host response to pathogens. *Nat Rev Immunol* (2006) 6(4):318-28. doi: 10.1038/nri1810

49. Borda ES, Sterin-Borda L. Antiadrenergic and muscarinic receptor antibodies in chagas' cardiomyopathy. *Int J Cardiol* (1996) 54(2):149-56. doi: 10.1016/j.ajpath.2014.12.023

50. Bonney KM, Engman DM. Autoimmune pathogenesis of chagas heart disease. *Am J Pathol* (2015) 185(6):1537-47. doi: 10.1016/j.ajpath.2014.12.023

51. Machado FS, Dutra WO, Esper L, Gollob K, Teixeira MM, Factor SM, et al. Current understanding of immunity to trypanosoma cruzi infection and pathogenesis of chagas disease. *Semin Immunopathol* (2012) 34(6):753-70. doi: 10.1007/s00281-012-0351-7

52. Chevillard C, Nunes JPS, Frade AF, Almeida RR, Pandey RP, Nascimento MS, et al. Disease tolerance and pathogen resistance genes may underlie trypanosoma cruzi persistence and differential progression to chagas disease cardiomyopathy. *Front Immunol* (2018) 9:2791. doi: 10.3389/fimmu.2018.02791

53. O'Connell RM, Taganov KD, Boldin MP, Cheng G, Baltimore D. MicroRNA-155 is induced during the macrophage inflammatory response. *Proc Natl Acad Sci U S A* (2007) 104(5):1604-9. doi: 10.1073/pnas.0610731104

54. Corsten MF, Papageorgiou A, Verhesen W, Carai P, Lindow M, Obad S, et al. MicroRNA profiling identifies microRNA-155 as an adverse mediator of cardiac injury and dysfunction during acute viral myocarditis. *Circ Res* (2012) 111(4):415-25. doi: 10.1161/CIRCRESAHA.112.267443

55. Kanhere A, Hertweck A, Bhatia U, Gökmen MR, Perucha E, Jackson I, et al. T-Bet and GATA3 orchestrate Th1 and Th2 differentiation through lineage-specific targeting of distal regulatory elements. *Nat Commun* (2012) 3:1268. doi: 10.1038/ncomms2260

56. Kohu K, Ohmori H, Wong WF, Onda D, Wakoh T, Kon S, et al. The Runx3 transcription factor augments Th1 and down-modulates Th2 phenotypes by interacting with and attenuating GATA3. *J Immunol* (2009) 183(12):7817-24. doi: 10.4049/jimmunol.0802527

57. Talebi F, Ghorbani S, Chan WF, Boghozian R, Masoumi F, Ghasemi S, et al. MicroRNA-142 regulates inflammation and T cell differentiation in an animal model of multiple sclerosis. *J Neuroinflammation* (2017) 14:55. doi: 10.1186/s12974-017-0832-7

58. Nogueira LG, Santos RHB, Fiorelli AI, Mairena EC, Benvenuti LA, Bocchi EA, et al. Myocardial gene expression of T-bet, GATA-3, ror-γt, FoxP3, and hallmark cytokines in chronic chagas disease cardiomyopathy: an essentially unopposed TH1-type response. *Mediators Inflamm* (2014) 2014:914326. doi: 10.1155/2014/914326

59. Chae WJ, Bothwell ALM. Canonical and non-canonical wnt signaling in immune cells. *Trends Immunol* (2018) 39(10):830-47. doi: 10.1016/j.it.2018.08.006

60. Volpini X, Ambrosio LF, Brajin MA, Brugo MB, Aoki MP, Rivarola HW, et al. Wnt signaling plays a key role in the regulation of the immune response and cardiac damage during trypanosoma cruzi infection. *ACS Infect Dis* (2021) 7(3):566-78. doi: 10.1021/acsinfecdis.0c00590

61. Volpini X, Ambrosio LF, Fozzatti L, Insfran C, Stempin CC, Cervi L, et al. Trypanosoma cruzi exploits wnt signaling pathway to promote its intracellular replication in macrophages. *Front Immunol* (2018) 9:859. doi: 10.3389/fimmu.2018.00859

62. Wnt signaling pathways in myocardial infarction and the therapeutic effects of wnt pathway inhibitors | acta pharmacologica sinica. Available at: https://www.nature.com/articles/s41401-018-0060-4

63. Aisagbonhi O, Rai M, Ryzhov S, Atria N, Feoktistov I, Hatzopoulos AK. Experimental myocardial infarction triggers canonical wnt signaling and endothelial-to-mesenchymal transition. *Dis Model Mech* (2011) 4(4):469-83. doi: 10.1242/dmm.006510

64. Piersma B, Bank RA, Boersema M. Signaling in fibrosis: TGF-β, WNT, and YAP/TAZ converge. *Front Med* (Lausanne) (2015) 2:59. doi: 10.3389/fmed.2015.00059

65. Vallée A, Lecarpentier Y, Guillevin R, Vallée JN. Interactions between TGF-β1, canonical WNT/β-catenin pathway and PPAR γ in radiation-induced fibrosis. *Oncotarget* (2017) 8(52):90579-604. doi: 10.1038/ncomms1734

66. Akhmetshina A, Palumbo K, Dees C, Bergmann C, Venalis P, Zerr P, et al. Activation of canonical wnt signalling is required for TGF-β-mediated fibrosis. *Nat Commun* (2012) 3:735. doi: 10.1038/ncomms1734

67. Ferreira RR, de Souza EM, de Oliveira FL, Ferrão PM, Gomes LHF, Mendonça-Lima L, et al. Proteins involved on TGF-β pathway are up-regulated during the acute phase of experimental chagas disease. *Immunobiology* (2016) 221(5):587-94. doi: 10.1016/j.imbio.2016.01.009

68. Araújo-Jorge TC, Waghabi MC, Bailly S, Feige JJ. The TGF-β pathway as an emerging target for chagas disease therapy. *Clin Pharmacol Ther* (2012) 92(5):613-21. doi: 10.1038/clpt.2012.102

69. Li Y, Hiroi Y, Liao JK. Notch signaling as an important mediator of cardiac repair and regeneration after myocardial infarction. *Trends Cardiovasc Med* (2010) 20(7):228-31. doi: 10.1016/j.tcm.2011.11.006

70. Huang F, Zhu X, Hu XQ, Fang ZF, Tang L, Lu XL, et al. Mesenchymal stem cells modified with miR-126 release angiogenic factors and activate notch ligand delta-like-4, enhancing ischemic angiogenesis and cell survival. *Int J Mol Med* (2013) 31(2):484-92. doi: 10.3892/ijmm.2012.1200

71. MicroRNA-384-5p promotes endothelial progenitor cell proliferation and angiogenesis in cerebral ischemic stroke through the delta-likeligand 4-mediated notch signaling pathway. Available at:

72. Wu F, Yu B, Zhang X, Zhang Y. Cardioprotective effect of notch signaling on the development of myocardial infarction complicated by diabetes mellitus. *Exp Ther Med* (2017) 14(4):3447-54. doi: 10.3892/etm.2017.4932

73. Zhou XL, Fang YH, Wan L, Xu QR, Huang H, Zhu RR, et al. Notch signaling inhibits cardiac fibroblast to myofibroblast transformation by antagonizing TGF-β1/Smad3 signaling. *J Cell Physiol* (2019) 234(6):8834-45. doi: 10.1002/jcp.27543

74. Yu B, Song B. Notch 1 signalling inhibits cardiomyocyte apoptosis in ischaemic postconditioning. *Heart Lung Circ* (2014) 23(2):152-8. doi: 10.1016/j.hlc.2013.07.004

75. Boopathy AV, Pendergrass KD, Che PL, Yoon YS, Davis ME. Oxidative stress-induced Notch1 signaling promotes cardiogenic gene expression in mesenchymal stem cells. *Stem Cell Res Ther* (2013) 4(2):43. doi: 10.1186/scrt190

76. Tu L, Fang TC, Artis D, Shestova O, Pross SE, Maillard I, et al. Notch signaling is an important regulator of type 2 immunity. *J Exp Med* (2005) 202(8):1037-42. doi: 10.1084/jem.20050923

77. Guzmán-Rivera D, Liempi A, González-Herrera F, Fuentes-Retamal S, Carrillo I, Abarca P, et al. Simvastatin improves cardiac function through notch 1 activation in BALB/c mice with chronic chagas cardiomyopathy. *Antimicrob Agents Chemother* (2020) 64(8):e02141-19. doi: 10.1371/journal.pntd.0009874

78. Casares-Marfil D, Kerick M, Andrés-León E, Bosch-Nicolau P, Molina IChagas Genetics CYTED Network, et al. GWAS loci associated with chagas cardiomyopathy influences DNA methylation levels. *PLoS Negl Trop Dis* (2021) 15(10):e0009874. doi: 10.1371/journal.pntd.0009874

## COPYRIGHT

© 2022 Brochet, Ianni, Laugier, Frade, Silva Nunes, Teixeira, Mady, Ferreira, Ferré, Santos, Kuramoto, Cabantous, Steffen, Stolf, Pomerantzeff, Fiorelli, Bocchi, Pissetti, Saba, Cándido, Dias, Sampaio, Gaiotto, Marin-Neto, Fragata, Zaniratto, Siqueira, Peixoto, Rigaud, Bacal, Buck, Almeida, Lin-Wang, Schmidt, Martinelli, Hirata, Donadi, Costa Pereira, Rodrigues Junior, Puthier, Kalil, Spinelli, Cunha-Neto and Chevillard. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.